A Study of a New Drug Treatment for Acne

Approximately 400 male and female subjects with moderate facial acne vulgaris will be
enrolled in this randomized, multi-center study. Following satisfaction of entry criteria and
screening procedures, subjects will be randomized to either 1.2%, 2.4%, or 3.6% facial cream
(JNJ 10229570-AAA) or color-matched vehicle. Subjects will apply the study medication once
daily on the face for 12 weeks. Safety will be monitored throughout the study duration.
Efficacy will be assessed by facial lesion counts and by the investigator global evaluation
of acne severity at Baseline and at Weeks 2, 4, 6, 8, 10, and 12. Approximately 50 subjects
from one investigational site also will have serums collected at Weeks 6 and 12 for
evaluation of the multiple dose pharmacokinetics of JNJ 10229570-AAA cream.

Inclusion Criteria:

- 12 years of age or older, with moderate facial acne vulgaris as defined in the
protocol

- If female of childbearing potential, must take a pregnancy test and have a negative
result

- Females of childbearing potential must also agree to use an adequate method of birth
control, which would include:

- systemic birth control (Subjects must have been taking the same type of birth
control for at least 3 months prior to entering the study and must not change
type of birth control during the study)

- Condom with spermicide

- IUD. Females who have had a hysterectomy, bilateral oophorectomy or bilateral
tubal ligation are not required to use additional birth control methods

Exclusion Criteria:

- Known sensitivity to any of the ingredients in the study medication

- More than 3 nodulocystic acne lesions

- Use of acne treatments, therapies or medications within protocol-specified timeframes

- Presence of other skin conditions, diseases, or medical conditions that (per protocol
or in the opinion of the investigator) may require concurrent therapy, interfere with
the evaluation of the study medication, or compromise subject safety

- Excessive facial hair that may interfere with application of the medication and/or
evaluations